Cargando…

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

Mostrar otras versiones (1)

BACKGROUND: Antivirals are needed to combat the COVID-19 pandemic, which is caused by SARS-CoV-2. The clinically-proven protease inhibitor Camostat mesylate inhibits SARS-CoV-2 infection by blocking the virus-activating host cell protease TMPRSS2. However, antiviral activity of Camostat mesylate met...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoffmann, Markus, Hofmann-Winkler, Heike, Smith, Joan C., Krüger, Nadine, Arora, Prerna, Sørensen, Lambert K., Søgaard, Ole S., Hasselstrøm, Jørgen Bo, Winkler, Michael, Hempel, Tim, Raich, Lluís, Olsson, Simon, Danov, Olga, Jonigk, Danny, Yamazoe, Takashi, Yamatsuta, Katsura, Mizuno, Hirotaka, Ludwig, Stephan, Noé, Frank, Kjolby, Mads, Braun, Armin, Sheltzer, Jason M., Pöhlmann, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930809/ https://www.ncbi.nlm.nih.gov/pubmed/33676899 http://dx.doi.org/10.1016/j.ebiom.2021.103255

Ejemplares similares

Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
por: Hoffmann, Markus, et al.
Publicado: (2020)

Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions
por: Weiss, Johanna, et al.
Publicado: (2021)

Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat
por: Hempel, Tim, et al.
Publicado: (2020)

Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation
por: Hofmann-Winkler, Heike, et al.
Publicado: (2020)

Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia
por: Sakr, Yasser, et al.
Publicado: (2021)

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
por: Gunst, Jesper D., et al.
Publicado: (2021)

A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19
por: Kitagawa, Junsaku, et al.
Publicado: (2021)

TMPRSS11A activates the influenza A virus hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1
por: Zmora, Pawel, et al.
Publicado: (2018)

Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach
por: Sonawane, Kailas D., et al.
Publicado: (2021)

Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat
por: Sun, Gaohui, et al.
Publicado: (2021)

Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors
por: C, Amrutha M, et al.
Publicado: (2023)

Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2
por: Zhu, Haixia, et al.
Publicado: (2020)

Safety Evaluation and Population Pharmacokinetics of Camostat Mesylate and Its Major Metabolites Using a Phase I Study
por: Kim, Gwanyoung, et al.
Publicado: (2023)

TMPRSS2 Isoform 1 Activates Respiratory Viruses and Is Expressed in Viral Target Cells
por: Zmora, Pawel, et al.
Publicado: (2015)

Computational screening of camostat and related compounds against human TMPRSS2: A potential treatment of COVID-19
por: Sharma, Tanuj, et al.
Publicado: (2022)

Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties
por: Hempel, Tim, et al.
Publicado: (2021)

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19
por: Kosinsky, Yuri, et al.
Publicado: (2022)

Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial
por: Tobback, Els, et al.
Publicado: (2022)

Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2
por: Escalante, Diego E., et al.
Publicado: (2021)

Different residues in the SARS-CoV spike protein determine cleavage and activation by the host cell protease TMPRSS2
por: Reinke, Lennart Michel, et al.
Publicado: (2017)

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
por: Karolyi, M., et al.
Publicado: (2022)

Delineation of the Pasteurellaceae-specific GbpA-family of glutathione-binding proteins
por: Vergauwen, Bjorn, et al.
Publicado: (2011)

Camostat mesilate therapy for COVID-19
por: Uno, Yoshiharu
Publicado: (2020)

Camostat Does Not Inhibit the Proteolytic Activity of Neutrophil Serine Proteases
por: Assylbekova, Akmaral, et al.
Publicado: (2022)

A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste
por: Chupp, Geoffrey, et al.
Publicado: (2022)

gbpA and chiA genes are not uniformly distributed amongst diverse Vibrio cholerae
por: Fennell, Thea G., et al.
Publicado: (2021)

Perdeuterated GbpA Enables Neutron Scattering Experiments of a Lytic Polysaccharide Monooxygenase
por: Sørensen, H. V., et al.
Publicado: (2023)

H2 influenza A virus is not pathogenic in Tmprss2 knock-out mice
por: Lambertz, Ruth Lydia Olga, et al.
Publicado: (2020)

A Double-Blind, Randomized, Placebo-Controlled, Phase II Clinical Study To Evaluate the Efficacy and Safety of Camostat Mesylate (DWJ1248) in Adult Patients with Mild to Moderate COVID-19
por: Kim, Yeon-Sook, et al.
Publicado: (2022)

Two nucleotide second messengers regulate the production of the Vibrio cholerae colonization factor GbpA
por: Kariisa, Ankunda T., et al.
Publicado: (2015)

Evidence that two instead of one defective interfering RNA in influenza A virus-derived defective interfering particles (DIPs) does not enhance antiviral activity
por: Bdeir, Najat, et al.
Publicado: (2021)

Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations
por: Ramakrishnan, Jaganathan, et al.
Publicado: (2021)

Acute eosinophilic pneumonia caused by camostat mesilate: The first case report
por: Ota, Shinichiro, et al.
Publicado: (2016)

Secreted Aeromonas GlcNAc binding protein GbpA stimulates epithelial cell proliferation in the zebrafish intestine
por: Banse, Allison V., et al.
Publicado: (2023)

The Vibrio cholerae Colonization Factor GbpA Possesses a Modular Structure that Governs Binding to Different Host Surfaces
por: Wong, Edmond, et al.
Publicado: (2012)

Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial
por: Keitel, Verena, et al.
Publicado: (2021)

RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia
por: Seccia, Teresa Maria, et al.
Publicado: (2023)

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
por: Hoffmann, Markus, et al.
Publicado: (2020)

Simultaneous Treatment of COVID-19 With Serine Protease Inhibitor Camostat and/or Cathepsin L Inhibitor?
por: Bittmann, Stefan, et al.
Publicado: (2020)

Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2
por: Azouz, Nurit P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nc4epaknmcj1ehheii1apd5kuh